CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2018 results and corporate developments in a conference call on Oct. 31, 2018 at 8 a.m. ET.
The investor presentation may be downloaded starting at 8 a.m. ET from the Events and Presentations page of the Investor Relations section of Intellia’s website at intelliatx.com.
To join the call:
- U.S. callers should dial 866-548-4713 and use conference ID# 5893807, approximately five minutes before the call.
- International callers should click here to access dial-in information and use conference ID# 5893807, approximately five minutes before the call.
A replay of the call will be available on Intellia’s website, beginning on Oct. 31, 2018 at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.
Intellia Contacts:
Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
lindsey.trickett@intelliatx.com
Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
Source: Intellia Therapeutics, Inc.
